Loading…

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid

A hallmark of Alzheimer's disease (AD) brain is the amyloid β (Aβ) plaque, which is comprised of Aβ peptides. Multiple lines of evidence suggest that Aβ oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compa...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of neuroscience 2014-02, Vol.34 (8), p.2884-2897
Main Authors: Savage, Mary J, Kalinina, Juliya, Wolfe, Abigail, Tugusheva, Katherine, Korn, Rachel, Cash-Mason, Tanesha, Maxwell, Jill W, Hatcher, Nathan G, Haugabook, Sharie J, Wu, Guoxin, Howell, Bonnie J, Renger, John J, Shughrue, Paul J, McCampbell, Alexander
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443
cites cdi_FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443
container_end_page 2897
container_issue 8
container_start_page 2884
container_title The Journal of neuroscience
container_volume 34
creator Savage, Mary J
Kalinina, Juliya
Wolfe, Abigail
Tugusheva, Katherine
Korn, Rachel
Cash-Mason, Tanesha
Maxwell, Jill W
Hatcher, Nathan G
Haugabook, Sharie J
Wu, Guoxin
Howell, Bonnie J
Renger, John J
Shughrue, Paul J
McCampbell, Alexander
description A hallmark of Alzheimer's disease (AD) brain is the amyloid β (Aβ) plaque, which is comprised of Aβ peptides. Multiple lines of evidence suggest that Aβ oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compared in one-site and competitive ELISAs for oligomer binding specificity. A two-site ELISA for oligomers was developed using 19.3 coupled to a sensitive, bead-based fluorescent platform able to detect single photons of emitted light. The two-site ELISA was >2500× selective for Aβ oligomers over Aβ monomers with a limit of detection ∼ 0.09 pg/ml in human CSF. The lower limit of reliable quantification of the assay was 0.18 pg/ml and the antibody pairs recognized Aβ multimers comprised of either synthetic standards, or endogenous oligomers isolated from confirmed human AD and healthy control brain. Using the assay, a significant 3- to 5-fold increase in Aβ oligomers in human AD CSF compared with comparably aged controls was demonstrated. The increase was seen in three separate human cohorts, totaling 63 AD and 54 controls. CSF oligomers ranged between 0.1 and 10 pg/ml. Aβ oligomer levels did not strongly associate with age or gender, but had an inverse correlation with MMSE score. The C statistic for the Aβ oligomer ROC curve was 0.86, with 80% sensitivity and 88% specificity to detect AD, suggesting reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker.
doi_str_mv 10.1523/JNEUROSCI.1675-13.2014
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6608513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1827915080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443</originalsourceid><addsrcrecordid>eNpVkU1OHDEQha2IKEwgV0DehU1Pyv_dG6TRCAgIgZTAMrKMu3ow8rQn7R4kOBYH4Ux4BBmRVS3eq1ev9BFywGDKFBc_zi-Pb35d_Z6fTZk2qmJiyoHJT2RS1KbiEtgOmQA3UGlp5C75mvM9ABhg5gvZ5VIp0QiYkD8zmrHPYQwPSN3LM00xLNISB-pydo-0DdkPYRl6N2Kms_h0h6Go3zN1fUvdAlvqUz8OKVKPA94OKa-KOdIurkO7Tz53Lmb89j73yM3J8fX8Z3VxdXo2n11UXkozVtI0HW9Lf9ZI5L6WDQrgtVcN16h5mY5r3jqN4NHXTa3BtJ5xUF3NlJRijxy95a7Wt0tsPZZGLtpVae6GR5tcsP8rfbizi_RgtYZaMVECDt8DhvR3jXm0y_I4xuh6TOtsWc1NwxTUUKz6zerLr3nAbnuGgd2wsVs2dsPGMmE3bMriwceS27V_MMQrI16Nig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1827915080</pqid></control><display><type>article</type><title>A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid</title><source>Open Access: PubMed Central</source><creator>Savage, Mary J ; Kalinina, Juliya ; Wolfe, Abigail ; Tugusheva, Katherine ; Korn, Rachel ; Cash-Mason, Tanesha ; Maxwell, Jill W ; Hatcher, Nathan G ; Haugabook, Sharie J ; Wu, Guoxin ; Howell, Bonnie J ; Renger, John J ; Shughrue, Paul J ; McCampbell, Alexander</creator><creatorcontrib>Savage, Mary J ; Kalinina, Juliya ; Wolfe, Abigail ; Tugusheva, Katherine ; Korn, Rachel ; Cash-Mason, Tanesha ; Maxwell, Jill W ; Hatcher, Nathan G ; Haugabook, Sharie J ; Wu, Guoxin ; Howell, Bonnie J ; Renger, John J ; Shughrue, Paul J ; McCampbell, Alexander</creatorcontrib><description>A hallmark of Alzheimer's disease (AD) brain is the amyloid β (Aβ) plaque, which is comprised of Aβ peptides. Multiple lines of evidence suggest that Aβ oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compared in one-site and competitive ELISAs for oligomer binding specificity. A two-site ELISA for oligomers was developed using 19.3 coupled to a sensitive, bead-based fluorescent platform able to detect single photons of emitted light. The two-site ELISA was &gt;2500× selective for Aβ oligomers over Aβ monomers with a limit of detection ∼ 0.09 pg/ml in human CSF. The lower limit of reliable quantification of the assay was 0.18 pg/ml and the antibody pairs recognized Aβ multimers comprised of either synthetic standards, or endogenous oligomers isolated from confirmed human AD and healthy control brain. Using the assay, a significant 3- to 5-fold increase in Aβ oligomers in human AD CSF compared with comparably aged controls was demonstrated. The increase was seen in three separate human cohorts, totaling 63 AD and 54 controls. CSF oligomers ranged between 0.1 and 10 pg/ml. Aβ oligomer levels did not strongly associate with age or gender, but had an inverse correlation with MMSE score. The C statistic for the Aβ oligomer ROC curve was 0.86, with 80% sensitivity and 88% specificity to detect AD, suggesting reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker.</description><identifier>ISSN: 0270-6474</identifier><identifier>EISSN: 1529-2401</identifier><identifier>DOI: 10.1523/JNEUROSCI.1675-13.2014</identifier><identifier>PMID: 24553930</identifier><language>eng</language><publisher>United States: Society for Neuroscience</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Aging - cerebrospinal fluid ; Alzheimer Disease - cerebrospinal fluid ; Alzheimer Disease - diagnosis ; Alzheimer Disease - psychology ; Amyloid beta-Peptides - cerebrospinal fluid ; Amyloid beta-Peptides - immunology ; Antibodies - immunology ; Antibody Specificity ; Biomarkers - cerebrospinal fluid ; Enzyme-Linked Immunosorbent Assay ; False Positive Reactions ; Female ; Humans ; Male ; Middle Aged ; Neuropsychological Tests ; Peptide Fragments - cerebrospinal fluid ; Reproducibility of Results ; ROC Curve ; Scattering, Radiation</subject><ispartof>The Journal of neuroscience, 2014-02, Vol.34 (8), p.2884-2897</ispartof><rights>Copyright © 2014 the authors 0270-6474/14/342884-14$15.00/0 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443</citedby><cites>FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608513/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608513/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24553930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Savage, Mary J</creatorcontrib><creatorcontrib>Kalinina, Juliya</creatorcontrib><creatorcontrib>Wolfe, Abigail</creatorcontrib><creatorcontrib>Tugusheva, Katherine</creatorcontrib><creatorcontrib>Korn, Rachel</creatorcontrib><creatorcontrib>Cash-Mason, Tanesha</creatorcontrib><creatorcontrib>Maxwell, Jill W</creatorcontrib><creatorcontrib>Hatcher, Nathan G</creatorcontrib><creatorcontrib>Haugabook, Sharie J</creatorcontrib><creatorcontrib>Wu, Guoxin</creatorcontrib><creatorcontrib>Howell, Bonnie J</creatorcontrib><creatorcontrib>Renger, John J</creatorcontrib><creatorcontrib>Shughrue, Paul J</creatorcontrib><creatorcontrib>McCampbell, Alexander</creatorcontrib><title>A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid</title><title>The Journal of neuroscience</title><addtitle>J Neurosci</addtitle><description>A hallmark of Alzheimer's disease (AD) brain is the amyloid β (Aβ) plaque, which is comprised of Aβ peptides. Multiple lines of evidence suggest that Aβ oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compared in one-site and competitive ELISAs for oligomer binding specificity. A two-site ELISA for oligomers was developed using 19.3 coupled to a sensitive, bead-based fluorescent platform able to detect single photons of emitted light. The two-site ELISA was &gt;2500× selective for Aβ oligomers over Aβ monomers with a limit of detection ∼ 0.09 pg/ml in human CSF. The lower limit of reliable quantification of the assay was 0.18 pg/ml and the antibody pairs recognized Aβ multimers comprised of either synthetic standards, or endogenous oligomers isolated from confirmed human AD and healthy control brain. Using the assay, a significant 3- to 5-fold increase in Aβ oligomers in human AD CSF compared with comparably aged controls was demonstrated. The increase was seen in three separate human cohorts, totaling 63 AD and 54 controls. CSF oligomers ranged between 0.1 and 10 pg/ml. Aβ oligomer levels did not strongly associate with age or gender, but had an inverse correlation with MMSE score. The C statistic for the Aβ oligomer ROC curve was 0.86, with 80% sensitivity and 88% specificity to detect AD, suggesting reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aging - cerebrospinal fluid</subject><subject>Alzheimer Disease - cerebrospinal fluid</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - psychology</subject><subject>Amyloid beta-Peptides - cerebrospinal fluid</subject><subject>Amyloid beta-Peptides - immunology</subject><subject>Antibodies - immunology</subject><subject>Antibody Specificity</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>False Positive Reactions</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuropsychological Tests</subject><subject>Peptide Fragments - cerebrospinal fluid</subject><subject>Reproducibility of Results</subject><subject>ROC Curve</subject><subject>Scattering, Radiation</subject><issn>0270-6474</issn><issn>1529-2401</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVkU1OHDEQha2IKEwgV0DehU1Pyv_dG6TRCAgIgZTAMrKMu3ow8rQn7R4kOBYH4Ux4BBmRVS3eq1ev9BFywGDKFBc_zi-Pb35d_Z6fTZk2qmJiyoHJT2RS1KbiEtgOmQA3UGlp5C75mvM9ABhg5gvZ5VIp0QiYkD8zmrHPYQwPSN3LM00xLNISB-pydo-0DdkPYRl6N2Kms_h0h6Go3zN1fUvdAlvqUz8OKVKPA94OKa-KOdIurkO7Tz53Lmb89j73yM3J8fX8Z3VxdXo2n11UXkozVtI0HW9Lf9ZI5L6WDQrgtVcN16h5mY5r3jqN4NHXTa3BtJ5xUF3NlJRijxy95a7Wt0tsPZZGLtpVae6GR5tcsP8rfbizi_RgtYZaMVECDt8DhvR3jXm0y_I4xuh6TOtsWc1NwxTUUKz6zerLr3nAbnuGgd2wsVs2dsPGMmE3bMriwceS27V_MMQrI16Nig</recordid><startdate>20140219</startdate><enddate>20140219</enddate><creator>Savage, Mary J</creator><creator>Kalinina, Juliya</creator><creator>Wolfe, Abigail</creator><creator>Tugusheva, Katherine</creator><creator>Korn, Rachel</creator><creator>Cash-Mason, Tanesha</creator><creator>Maxwell, Jill W</creator><creator>Hatcher, Nathan G</creator><creator>Haugabook, Sharie J</creator><creator>Wu, Guoxin</creator><creator>Howell, Bonnie J</creator><creator>Renger, John J</creator><creator>Shughrue, Paul J</creator><creator>McCampbell, Alexander</creator><general>Society for Neuroscience</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20140219</creationdate><title>A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid</title><author>Savage, Mary J ; Kalinina, Juliya ; Wolfe, Abigail ; Tugusheva, Katherine ; Korn, Rachel ; Cash-Mason, Tanesha ; Maxwell, Jill W ; Hatcher, Nathan G ; Haugabook, Sharie J ; Wu, Guoxin ; Howell, Bonnie J ; Renger, John J ; Shughrue, Paul J ; McCampbell, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aging - cerebrospinal fluid</topic><topic>Alzheimer Disease - cerebrospinal fluid</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - psychology</topic><topic>Amyloid beta-Peptides - cerebrospinal fluid</topic><topic>Amyloid beta-Peptides - immunology</topic><topic>Antibodies - immunology</topic><topic>Antibody Specificity</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>False Positive Reactions</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuropsychological Tests</topic><topic>Peptide Fragments - cerebrospinal fluid</topic><topic>Reproducibility of Results</topic><topic>ROC Curve</topic><topic>Scattering, Radiation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Savage, Mary J</creatorcontrib><creatorcontrib>Kalinina, Juliya</creatorcontrib><creatorcontrib>Wolfe, Abigail</creatorcontrib><creatorcontrib>Tugusheva, Katherine</creatorcontrib><creatorcontrib>Korn, Rachel</creatorcontrib><creatorcontrib>Cash-Mason, Tanesha</creatorcontrib><creatorcontrib>Maxwell, Jill W</creatorcontrib><creatorcontrib>Hatcher, Nathan G</creatorcontrib><creatorcontrib>Haugabook, Sharie J</creatorcontrib><creatorcontrib>Wu, Guoxin</creatorcontrib><creatorcontrib>Howell, Bonnie J</creatorcontrib><creatorcontrib>Renger, John J</creatorcontrib><creatorcontrib>Shughrue, Paul J</creatorcontrib><creatorcontrib>McCampbell, Alexander</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Savage, Mary J</au><au>Kalinina, Juliya</au><au>Wolfe, Abigail</au><au>Tugusheva, Katherine</au><au>Korn, Rachel</au><au>Cash-Mason, Tanesha</au><au>Maxwell, Jill W</au><au>Hatcher, Nathan G</au><au>Haugabook, Sharie J</au><au>Wu, Guoxin</au><au>Howell, Bonnie J</au><au>Renger, John J</au><au>Shughrue, Paul J</au><au>McCampbell, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid</atitle><jtitle>The Journal of neuroscience</jtitle><addtitle>J Neurosci</addtitle><date>2014-02-19</date><risdate>2014</risdate><volume>34</volume><issue>8</issue><spage>2884</spage><epage>2897</epage><pages>2884-2897</pages><issn>0270-6474</issn><eissn>1529-2401</eissn><abstract>A hallmark of Alzheimer's disease (AD) brain is the amyloid β (Aβ) plaque, which is comprised of Aβ peptides. Multiple lines of evidence suggest that Aβ oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compared in one-site and competitive ELISAs for oligomer binding specificity. A two-site ELISA for oligomers was developed using 19.3 coupled to a sensitive, bead-based fluorescent platform able to detect single photons of emitted light. The two-site ELISA was &gt;2500× selective for Aβ oligomers over Aβ monomers with a limit of detection ∼ 0.09 pg/ml in human CSF. The lower limit of reliable quantification of the assay was 0.18 pg/ml and the antibody pairs recognized Aβ multimers comprised of either synthetic standards, or endogenous oligomers isolated from confirmed human AD and healthy control brain. Using the assay, a significant 3- to 5-fold increase in Aβ oligomers in human AD CSF compared with comparably aged controls was demonstrated. The increase was seen in three separate human cohorts, totaling 63 AD and 54 controls. CSF oligomers ranged between 0.1 and 10 pg/ml. Aβ oligomer levels did not strongly associate with age or gender, but had an inverse correlation with MMSE score. The C statistic for the Aβ oligomer ROC curve was 0.86, with 80% sensitivity and 88% specificity to detect AD, suggesting reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker.</abstract><cop>United States</cop><pub>Society for Neuroscience</pub><pmid>24553930</pmid><doi>10.1523/JNEUROSCI.1675-13.2014</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-6474
ispartof The Journal of neuroscience, 2014-02, Vol.34 (8), p.2884-2897
issn 0270-6474
1529-2401
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6608513
source Open Access: PubMed Central
subjects Adult
Aged
Aged, 80 and over
Aging - cerebrospinal fluid
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - diagnosis
Alzheimer Disease - psychology
Amyloid beta-Peptides - cerebrospinal fluid
Amyloid beta-Peptides - immunology
Antibodies - immunology
Antibody Specificity
Biomarkers - cerebrospinal fluid
Enzyme-Linked Immunosorbent Assay
False Positive Reactions
Female
Humans
Male
Middle Aged
Neuropsychological Tests
Peptide Fragments - cerebrospinal fluid
Reproducibility of Results
ROC Curve
Scattering, Radiation
title A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A35%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20sensitive%20a%CE%B2%20oligomer%20assay%20discriminates%20Alzheimer's%20and%20aged%20control%20cerebrospinal%20fluid&rft.jtitle=The%20Journal%20of%20neuroscience&rft.au=Savage,%20Mary%20J&rft.date=2014-02-19&rft.volume=34&rft.issue=8&rft.spage=2884&rft.epage=2897&rft.pages=2884-2897&rft.issn=0270-6474&rft.eissn=1529-2401&rft_id=info:doi/10.1523/JNEUROSCI.1675-13.2014&rft_dat=%3Cproquest_pubme%3E1827915080%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-479f2d014194e2c849e3028c5926e62c59a262da6e0cec898607dc1205f815443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1827915080&rft_id=info:pmid/24553930&rfr_iscdi=true